• The Janssen Pharmaceutical Companies of Johnson & Johnson  unveils longer-term results from the combined Phase 1b/2 CARTITUDE-1 study evaluating ciltacabtagene autoleucel (cilta-cel) for the treatment of patients with relapsed and/or refractory multiple myeloma.
  • Cilta-cel is an experimental BCMA-directed (B cell maturation antigen) chimeric antigen receptor T cell (CAR-T) therapy.
  • Data presented at the ongoing Annual Meeting of the American Society of Hematology 2020 demonstrated a very high overall response rate of 97 percent, with 67 percent of patients achieving a stringent complete response. With a median follow-up of 12.4 months, the median duration of response and progression-free survival were not reached, according to investigators.
  • Notably, though, fourteen deaths were reported during the study, including six due to adverse events related to treatment.
  • Most common hematologic adverse events (AEs) observed in the CARTITUDE-1 study were neutropenia (96 percent); anemia (81 percent); thrombocytopenia (79 percent); leukopenia (62 percent); and lymphopenia (53 percent). Neurotoxicity of any grade was observed in 21 percent (n=20) of patients.
Share Button